Novavax ($NVAX) pump and dump saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its marks across the 12,000-strong study many workers were laid off from Fujifilms manufacturing and we're with no plans of ever selling products.
In top-line data released just after the markets closed, the biotech’s RSV F-protein recombinant nanoparticle vaccine candidate failed to hit both its primary and secondary objectives, and most damning of all, did not demonstrate vaccine efficacy in the Phase III Resolve trial.
Novavax sunk by nearly 70% by value Thursday after the biotech announced a Phase 3 study of its experimental vaccine ResVax failed to achieve its main goal. The trial featured 4,636 pregnant women, two-thirds of whom were randomly selected to receive the company's vaccine while the remaining one-third were given placebo. Topline results showed the vaccine did not meet the primary endpoint of preventing medically significant respiratory syncytial virus (RSV) lower respiratory tract infections in infants three months after delivery.
Novavax Reviews
Novavax ($NVAX) pump and dump saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its marks across the 12,000-strong study many workers were laid off from Fujifilms manufacturing and we're with no plans of ever selling products.
In top-line data released just after the markets closed, the biotech’s RSV F-protein recombinant nanoparticle vaccine candidate failed to hit both its primary and secondary objectives, and most damning of all, did not demonstrate vaccine efficacy in the Phase III Resolve trial.
Novavax sunk by nearly 70% by value Thursday after the biotech announced a Phase 3 study of its experimental vaccine ResVax failed to achieve its main goal. The trial featured 4,636 pregnant women, two-thirds of whom were randomly selected to receive the company's vaccine while the remaining one-third were given placebo. Topline results showed the vaccine did not meet the primary endpoint of preventing medically significant respiratory syncytial virus (RSV) lower respiratory tract infections in infants three months after delivery.